Healthcare

Quarterly revenue of $90.4 million reflects the combined activity of the laboratory and therapeutic businesses. The release describes the laboratory services unit as well established, while the therapeutic development unit is at an earlier commercial stage. The mix between these two areas shapes how …

The decline in short-term investments accounts for most of the drop in total cash. Because the release describes the reduction as primarily a shift within theInvestmentportfolio, the change does not on its own indicate a spending increase of the same size, though the fullCash …

Infusion Systems revenue rose 10.7 percent to $192.5 million, adding $18.6 million year over year. Consumables revenue increased 4.7 percent to $298.4 million, supported by a $13.3 million gain. Vital Care revenue declined $8.5 million to $69.5 million, a result tied to the May …

Because of the divestiture of the rental business, Inogen removed that activity from its forward figures. Guidance from continuing operations gives a clearer view of theBusinessthe company intends to keep, but it also means that headline revenue numbers will not match prior periods that …

System-wide sales were $123.3 million, a decrease of 3.1 percent from the third quarter of 2025. Reported comparable sales declined 1.9 percent, an improvement from the 2.8 percent decline in the second quarter. The narrower decline indicates that same-clinic sales fell by less than …

NKX019 is the company's lead program, and the release describes its progress in myositis and systemic sclerosis as the main focus of the period. Autoimmune indications are often pursued in parallel, and the company's choice of two lead indications concentrates its clinical effort on …

Oncology tests were the fastest-growing category, with about 339,500 processed in the quarter, up 60.9 percent from roughly 211,000 a year earlier. Clinical molecular residual disease oncology units grew by 32,700 over the second quarter, a figure that highlights how quickly this testing category …